Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period 2018 to 2023| Dominant Players - PFIZER LIMITED, BOEHRINGER INGELHEIM, BAYER AG, GLAXOSMITHKLINE PLC, NOVARTIS AG, amongst others

Market Analysis:

North America to Dominate the Market
North America dominates the urinary tract infection therapeutics market due to high UTI detection along with increasing diabetes prevalence in the region. Europe is also expected to boost the UTI therapeutics market owing to increased accessibility to healthcare facilities along with high UTI prevalence among the population.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16743
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

According to World Health Organization (WHO), in 1980 there were 108 million people suffering from diabetes, this number increased to 422 million in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue in the forecast period. Therefore with increasing prevalence, the number of UTI increases, and with increase in UTI, the demand for drugs increases. Thus increasing prevalence of diabetes worldwide is expected to act as a major driver for the global urinary tract infection therapeutics market. In addition, launch of combination drugs which are more effective and increasing geriatric population are also expected to boost the growth of urinary tract infection therapeutics market. Increasing cases of Adverse Drug Reactions (ADRs) is acting as a major restraint for the UTI therapeutics market.

Request Discount on this report @ https://marketprognosis.com/discount-request/16743
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
UTI Therapeutics Market is segmented by:
1. DRUG TYPE: PENICILLIN & COMBINATIONS, QUINOLONES, CEPHALOSPORIN, AMINOGLYCOSIDE ANTIBODIES, SULPHONAMIDES, AZOLES & AMPHOTERICIN B, TETRACYCLINE, NITROFURANS, OTHERS
2. INDICATION TYPE: COMPLICATED UTI, RECURRING COMPLICATED UTI, UNCOMPLICATED UTI, NEUROGENIC BLADDER INFECTION
3. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa

Key Developments in the Market
• August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam.
• December 2017: F.D.A has accepted for review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) on June, 2018.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/16743
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.